Skip to main content

stock

ANTX · AN2 Therapeutics, Inc.

What AN2 Therapeutics, Inc. reports to the SEC, read from its filings.

Open in the app

Price

The live ANTX price and today's change.

Sign in to see this

Chart

Thirty days of daily bars, with signal levels drawn on them.

Sign in to see this

Signals

The latest signal group Nakagai's scanner recorded on ANTX.

Sign in to see this

Options positioning

Gamma exposure levels from the options market.

Sign in to see this

Technicals

Trend, momentum and volatility gauges per timeframe.

Sign in to see this

What it is

Industry
Pharmaceutical Preparations (SIC 2834)
Filer (SEC EDGAR)
EDGAR filing index
Shares outstanding
37,736,237 as of 2026-08-06 (XBRL frame CY2026Q2I)

Key stats

Valuation

P/E
Locked
P/S
Locked
P/B
Locked
Enterprise value
Locked
EV/EBIT
Locked
FCF yield
Locked

Margins

Gross
—
Operating
—
Net
—

Returns

ROE
-47.8%
ROA
-44.4%

Health

Current ratio
14.3x
Debt/equity
—

Deep value

NCAV
$74.24M
NCAV per share
$1.97
Price/NCAV
Locked
NNWC
$38.56M
NNWC per share
$1.02
Price/NNWC
Locked

Valuation and the price multiples are built on the live price. Trailing twelve months to 2026-06-30; balance sheet at 2026-06-30.

Sign in to see this

Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.

Results

Period endRevenue (not reported by this company)Gross profit (not reported by this company)Operating incomeNet incomeFiling
2026-06-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$8.90M-$8.19M
10-Q filed 2026-08-11
2026-03-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$10.55M-$10.03M
10-Q filed 2026-08-11
Assembled from more than one filing; the filing above is only the newest of them.
2025-12-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$9.32M-$8.71M
10-K filed 2026-03-17
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2025-09-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$10.04M-$9.35M
10-Q filed 2025-11-12
2025-06-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$7.22M-$6.46M
10-Q filed 2026-08-11
2025-03-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$11.54M-$10.65M
10-Q filed 2026-08-11
Assembled from more than one filing; the filing above is only the newest of them.
2024-12-31—Revenue: unreported by this company.—Gross profit: unreported by this company.-$8.60M-$7.52M
10-K filed 2026-03-17
Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter.
2024-09-30—Revenue: unreported by this company.—Gross profit: unreported by this company.-$14.01M-$12.75M
10-Q filed 2025-11-12
Assets
$81.68M
Equity
$75.92M

Balance as of 2026-06-30.

Ten years

Fiscal year endRevenueOperating incomeNet incomeFree cash flow
2025-12-31—-$38.11M-$35.17M—
2024-12-31—-$56.79M-$51.32M—
2023-12-31—-$69.64M-$64.73M—
2022-12-31—-$42.26M-$40.96M—
2021-12-31—-$21.57M-$21.54M—

Company filings

since Thu Apr 9 · 2 offering filings in 12 months · since Mon Apr 20

events

  • Results

    Results
    Aug 118-K
  • Shareholder vote results

    Shareholder vote results
    Jun 88-K
  • Regulation FD disclosure, Other event

    Regulation FD disclosureOther event
    Jun 48-K
  • Results

    Results
    May 118-K
  • Other event

    Other event
    Apr 98-K
  • Executive or director change

    Executive or director change
    Mar 208-K

5% owners ()

Insiders, politicians and funds

Insider trades, last 90 days

Politician trades, last 90 days

Funds

None of the tracked funds held this at their last 13F.

News

Stories that named ANTX, and the market events around them.

Sign in to see this

Board

The ANTX board could not be loaded.

Retry the ANTX board

nakagai

Signals on ANTX come from a rule, not a model.

Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.

Members post on the ANTX board

This page is not financial advice. Trade at your own judgment and risk. Read the terms that govern posting here.

AN2 Therapeutics, Inc. (ANTX): SEC filings, financials and insider trades · Nakagai